Streetbeat News

Analyst Ratings

DNA

TD Cowen analyst Steven Mah maintains an Outperform rating on Ginkgo Bioworks Holdings (NYSE:DNA) but lowers the price target from $7 to $3.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:50 pm

CELH

Stifel analyst Mark Astrachan maintains a Buy rating on Celsius Holdings (CELH) and raises the price target from $67 to $90.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:50 pm

ADSK

Stifel analyst Adam Borg maintains a Buy rating on Autodesk (ADSK) and raises the price target from $265 to $316.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:48 pm

NUVB

Wedbush analyst David Nierengarten reiterates an Outperform rating on Nuvation Bio (NUVB) and maintains a $5 price target. This reaffirmation highlights the analyst's positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:46 pm

PTCT

TD Cowen analyst Joseph Thome has maintained a Market Perform rating on PTC Therapeutics (NASDAQ:PTCT) and lowered the price target from $32 to $30.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:44 pm

VCEL

Truist Securities analyst Samuel Brodovsky has maintained a Buy rating on Vericel (NASDAQ:VCEL) and increased the price target from $51 to $54.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:44 pm

ORIC

Wedbush analyst David Nierengarten maintains an Outperform rating on ORIC Pharmaceuticals (NASDAQ:ORIC) and raises the price target from $12 to $20.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:43 pm

VEEV

Truist Securities analyst Jailendra Singh has maintained a Hold rating on Veeva Systems (VEEV) and increased the price target from $187 to $203.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:42 pm

UNIT

TD Cowen analyst Gregory Williams maintains an Outperform rating on Uniti Group (NASDAQ:UNIT) and raises the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:42 pm

XENE

Wedbush analyst Laura Chico maintains an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) and raises the price target from $46 to $51.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:41 pm